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Abstract
Background: A characteristic SYT–SSX fusion gene resulting from the chromosomal translocation t(X;18)(p11;q11) is
detectable in almost all synovial sarcomas, a malignant soft tissue tumor widely believed to originate from as yet
unidentified pluripotent stem cells. The resulting fusion protein has no DNA binding motifs but possesses protein-protein
interaction domains that are believed to mediate association with chromatin remodeling complexes. Despite recent
advances in the identification of molecules that interact with SYT-SSX and with the corresponding wild type SYT and SSX
proteins, the mechanisms whereby the SYT-SSX might contribute to neoplastic transformation remain unclear. Epigenetic
deregulation has been suggested to be one possible mechanism.
Methodology/Principal Findings: We addressed the effect of SYT/SSX expression on the transcriptome of four independent
isolates of primary human bone marrow mesenchymal stem cells (hMSC). We observed transcriptional changes similar to
the gene expression signature of synovial sarcoma, principally involving genes whose regulation is linked to epigenetic
factors, including imprinted genes, genes with transcription start sites within a CpG island and chromatin related genes.
Single population analysis revealed hMSC isolate-specific transcriptional changes involving genes that are important for
biological functions of stem cells as well as genes that are considered to be molecular markers of synovial sarcoma including
IGF2, EPHRINS, and BCL2. Methylation status analysis of sequences at the H19/IGF2 imprinted locus indicated that distinct
epigenetic features characterize hMSC populations and condition the transcriptional effects of SYT-SSX expression.
Conclusions/Significance: Our observations suggest that epigenetic features may define the cellular microenvironment in
which SYT-SSX displays its functional effects.
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Introduction
Synovial sarcoma (SS) is an aggressive soft tissue tumor that
accounts for about 10% of all human sarcomas [1–3] and is found
throughout the body. It arises in adolescents and young adults and
is associated with poor prognosis despite multimodal therapy.
Current opinion holds that sarcomas, including synovial sarcoma,
are derived from as yet unidentified multipotent stem cells capable
of mesenchymal and neuroectodermal differentiation.
More than 90% of synovial sarcomas are characterized by a
specific chromosomal translocation, t(X:18)(p11.2: q11.2), that
results in the fusion of the SYT gene on chromosome 18 to one of
several SSX gene family members, (SSX1, SSX2 or SSX4), on
chromosome X.
The SYT and the SSX gene family encode nuclear proteins whose
function has yet to be fully defined. Neither protein has DNA
binding motifs but both possess protein-protein interaction domains
that are believed to mediate binding to transcriptional regulators.
When targeted to a reporter gene, SYT is shown to transactivate,
whereas SSX is observed to repress transcription [4,5].
SYT is a ubiquitously expressed 387 amino acid protein that
colocalizes and interacts in vitro through its evolutionarily
conserved N-terminal SNH (for SYT N-terminal Homology)
domain, with human BRM and BRG1, two mutually exclusive
ATPases that constitute part of the SWI/SNF complex, a global
chromatin remodeling transcriptional coactivator [6–8]. In
contrast to SYT, SSX proteins have a more restricted distribution,
being expressed primarily in the testis. Their C-terminal SSX-RD
domain is responsible for their nuclear localization, and for
colocalization with RING1 and Bmi-1, components of histone-
associated polycomb group proteins implicated in transcriptional
repressor activity [5,9].
Upon translocation, the most common fusion is generated by
the replacement of the 8 C-terminal amino acids of SYT by the 78
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SH2 C-terminal motif all SYT domains are retained in the SYT-
SSX fusion, along with the SSX-RD domain [10]. SYT, SSX and
the fusion protein appear to have distinct nuclear staining patterns,
but consistent with the presence of an intact SNH and SSX-RD
domain, SYT/SSX retains interaction with BRM and BRG1
as well as colocalization with the polycomb group proteins
[4,6,8,11,12]. Thus, the SYT-SSX fusion encodes two distinct
protein domains, which associate with chromatin remodeling
complexes that display opposing functions.
SYT-SSX proteins have been found to display limited
oncogenic potential in fibroblasts and various cell lines [13].
These observations suggest either that additional oncogenic events
are required for malignant transformation or that SYT-SSX can
display its oncogenic potential only in a specific cellular context.
Generation of the first transgenic model of SS is consistent with the
latter possibility [14]. Conditional expression of SYT-SSX2 in
myoblast precursors but not in myocytes resulted in tumors that
recapitulate many of the characteristics of human SS. These
studies highlight the importance of the timing of fusion transcript
expression during cell differentiation and the highly restricted
cellular context that is permissive for its oncogenic properties.
Despite discoveries that SYT and SSX associate with other
nuclear proteins [2,15–21], it remains unclear how SYT/SSX
might contribute to neoplastic transformation. Gene expression
profile comparison of SS to other sarcoma types has helped
identify a handful of genes that are preferentially associated with
SS [22–24] and suggests the implication of several signaling
pathways in SS pathogenesis, including receptor tyrosine kinases,
Hedgehog, Notch, RAR, TGFb and Wnt [25–29]. SYT/SSX has
been proposed to regulate cyclin D expression in SS cells [30,31],
to induce the cyclin-dependent kinase inhibitor (CKI) p21(WAF1/
CIP1) in various cell lines [32] and to negatively regulate, at least
in osteosarcoma cell lines, the stability of the tumor suppressor p53
by promoting HDM2 stabilization [33]. SYT-SSX2 has been
proposed to contribute to tumor development through b-catenin
signaling [34] and by altering the cytoskeletal architecture in an
ephrin-dependent manner [35].
Although molecular characterization of SS and the role of SYT-
SSX are beginning to provide insight into events that may be
important in shaping the biological behavior of the tumor,
numerous questions remain, including whether or not SYT-SSX
expression is sufficient for tumor formation and/or differentiation,
the nature of the downstream targets of SYT-SSX, and what
additional genes might be critical for the genesis of SS. Recent
studies have highlighted epigenetic mechanisms as the potential
basis for the effects induced by the expression of SYT-SSX [27].
The H19/IGF2 gene pair, which is the best characterized
imprinted chromatin barrier locus described to date, has been
proposed as a possible SYT/SSX target [36]. Similar to other
imprinted clusters, expression of H19 and IGF2 is jointly regulated
through an imprinting control region (ICR) of approximately
5 Kb in humans, located between the two genes. This region
functions by regulating interactions between H19 and IGF2
promoters and their shared enhancers, which are located
downstream of the H19 coding sequence and can, in the absence
of a chromatin barrier, stimulate transcription of the IGF2 gene in
cis. The methylation status of specific conserved sequences
regulates the binding of the ubiquitously expressed factor CTCF
to the ICR, which functions as an insulator and enhancer blocker.
In most adult tissues, binding of CTCF to the unmethylated
maternal allele prevents H19 enhancers from inducing IGF2
expression, leaving them available to induce H19. Methylation of
the paternal H19 ICR abrogates CTCF binding resulting in
enhancer stimulation of IGF2 expression and H19 silencing.
Recent studies using chromosome conformation capture (3C) have
shown that long range allele-specific interactions constitute part of
the insulation mechanism but our understanding of these
interactions is still incomplete. A complex three-dimensional,
multiple-loop model organized by the CTCF-ICR complex on the
maternal allele has been recently proposed [37]and both intra and
inter-chromosomal interactions have been shown to involve the
H19 ICR [38].
Loss of imprinting (LOI) concurrent to hypomethylation at the
H19/IGF2 intergenic region has been observed in a limited
number of primary synovial sarcomas [39] and SYT-SSX
expression has been shown to induce IGF2 in immortalized
MRC5 fibroblasts [39] and HEK 293 cells [27]. In the latter case,
IGF2 induction could be attributed to epigenetic mechanisms:
hypermethylation was observed at the H19/IGF2 intergenic region
and enrichment of histone marks associated with active chromatin
was observed at the IGF2 promoter. More recently, epigenetic
effects of SYT-SSX on other targets have been reported [40].
Thus, down-regulation of EGR1 by SYT-SSX expression in HEK
293 cells was shown to occur via histone modifications and
recruitment of polycomb proteins to the EGR1 promoter. Finally
the histone deacetylase (HDAC) inhibitor FK228 has been
reported to block synovial sarcoma cell growth both in vitro and
in vivo [20].
Most of these studies were conducted using cell lines that may
have acquired significant modifications of their epigenetic status
both during transformation and during prolonged cell culture.
They were therefore unlikely to fully recapitulate the biology of
primary in vivo tumor development. Thus, despite these potentially
relevant insights, it remains unclear whether the epigenetic effects
of SYT-SSX are required for tumor development, maintenance
and/or other biological properties of synovial sarcoma. The
precise mechanism of epigenetic deregulation by the synovial
sarcoma fusion protein has yet to be defined as do the epigenetic
features that may render primary cells permissive for SYT-SSX
functions and potential oncogenic properties.
To address these issues, we introduced the fusion gene into
primary human mesenchymal stem cells (hMSC), that may
constitute candidate cells of origin of SS, and assessed factors that
may influence SYT-SSX-mediated gene expression profile changes.
Our results show that the expression of SYT-SSX in hMSCs
induces a transcriptional profile that bears significant relatedness to
the synovial sarcoma expression signature. In these cells, SYT-SSX
primarily affects the expression of genes whose regulation is linked
to epigenetic factors, including imprinted genes, genes with
transcription start site (TSS) within a CpG island, and chromatin
related genes. Our results also highlight the notion that despite
uniform morphology and cell surface marker expression, different
MSC populations display distinct epigenetic features that appear to
influence transcriptional changes induced by SYT-SSX. These
observations suggest that the epigenetic status of primary cells may
determine the functional effect of SYT-SSX, possibly including its
transforming capacity.
Results
Expression of SYT-SSX1 Fusion Protein in Mesenchymal
Stem Cells
Human MSCs were obtained from femoral head bone marrow
of pediatric and adolescent patients undergoing limb axis re-
adjustment. Isolation of hMSCs was performed as previously
described [41,42]. Cells were maintained at low confluence and
tested periodically for their ability to differentiate into adipocytes,
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[41,42]. The four independent hMSC isolates did not display any
significant difference in multilineage differentiation tests, a
representative result of which is shown in figure S1.The SYT-
SSX1 fusion gene was amplified by RT-PCR from RNA derived
from a human synovial sarcoma specimen, ligated in-frame to a
V5 tag and introduced into a retroviral expression vector. Four
independent hMSC isolates were infected with corresponding
retroviruses using a Retroviral Gene Transfer and Expression
system. Expression of SYT-SSX1 RNA and protein were tested 12
days after infection and neomycin selection. Real time PCR
amplification, using primers complementary to sequences flanking
the SYT-SSX breakpoint, indicated similar levels of the
corresponding messenger RNA in each population (fig. 1B).
Western blot analysis using an anti-V5 tag antibody revealed
comparable SYT-SSX1 protein expression among the four
infected hMSC populations (fig. 1A). hMSCs expressing SYT-
SSX1 (hMSC
SYT-SSX1) displayed a survival rate comparable to
that of wt cells and maintained fusion protein expression for more
than 3 months (data not shown). However hMSC
SYT-SSX1 did not
undergo transformation, as assessed by their inability to form
tumors upon subcutaneous and sub-capsular renal injection into
immunocompromised mice.
Genes Regulated by SYT-SSX1 Expression in hMSC Are
Restricted to a Few Defined Categories
To assess the effect of SYT-SSX expression in hMSC,
transcriptome analysis was performed on the 4 independent
MSC
SYT-SSX1 populations 12 days after infection and neomycin
selection. The batches were first analyzed together with rank
products, resulting in lists of probe sets that were differentially
expressed with a false discovery rate (FDR) of 1% and a mean fold
change .2 (tableS2).Analysisof theselistsrevealedthatmanyofthe
genes regulated by SYT-SSX1 expression in hMSCs belong to a
restricted set of categories (table 1) that include imprinted genes,
genes that encode for chromatin associated proteins, and genes
having at least one transcript with a transcription start site (TSS)
within a CpG island. Based on these observations, we used several
databases to test the over-representation of specific gene categories
and perform statistical analysis, including: http://www.geneimprint.
com/ and http://igc.otago.ac.nz/home.html [43] for imprinted
genes, http://www.chromdb.org/ [44] for chromatin associated
protein and http://genome.ucsc.edu/ for genes containing CpG
island in the TSS.
Among the genes induced by SYT-SSX1 we found a
statistically significant over-representation of transcripts whose
TSS lies within a CpG island (P-value 0.0051) and a higher
than expected by chance number of chromatin-associated
genes, but with a non significant p-value. Analysis of both the
geneimprint and otago datasets of imprinted genes revealed
highly significant over-representation (p-value as low as 10
26)
of genes induced by SYT-SSX1. Comparison to geneimprint
lists restricted to experimentally confirmed imprinted genes
only produced an even higher significance (p value of 10
29)
than comparison to geneimprint lists inclusive of both
experimentally confirmed and predicted imprinted genes.
Over-representation of imprinted genes was not observed when
t h es a m ea n a l y s i sw a sp e r f o r m e do nt h et r a n s c r i p t o m eo fM S C s
infected with the Ewing’s sarcoma-associated fusion gene EWS-
FLI1 (data not shown).
Analysis of SYT-SSX1-Induced and Repressed Genes
According to Functional Annotation
Analysis of genes induced and repressed by SYT-SSX1 in
hMSCs, according to Gene Ontology (GO) annotation [45]
(http://www.geneontology.org/), revealed over-representation of
few GO terms among the induced genes with a P value,10
25.
Complete lists of GO annotation terms found to be significantly
over-represented in each set of induced and repressed genes are
available (supplementary data 3). Several of the GO terms,
including ‘‘extracellular region’’ and ‘‘integral to plasma mem-
brane’’ encompass a broad range of genes and have limited
informative value. However, numerous induced genes were found
to be associated with more specific annotations of potential
functional relevance (table 1 and supplementary data 3).
Over represented GO annotation terms of potential interest
among transcripts induced by SYT-SSX1 in hMSCs included
‘‘nervous system development’’ and ‘‘central nervous system
development’’, consistent with the possibility that SYT-SSX1
exerts pressure toward neuronal differentiation in pluripotent stem
cells. Genes induced by SYT-SSX1 belonging to these GO terms
include the predicted imprinted genes HES1, SOX8 and SPON2, all
of which have CpG islands in their TSS. It is therefore possible
that SYT-SSX may affect the expression of functionally related
groups of genes through a general mechanism that perturbs
methylation and imprinting.
Figure 1. Expression of SYT-SSX1 fusion protein in human
MSCs. Four different batches of human MSCs were infected with
pMSCV-SYT-SSX1-v5 (lanes 2, 4, 6, 8) or an empty pMSCV neo vector
(lanes 1,3, 5, 7), and cells were selected with 0.5 mg/ml G418 and
harvested 12 days after infection. (A) Protein expression was assessed
by western blot analysis using a mouse anti-v5 monoclonal antibody
and HRP-conjugated goat anti mouse IgG. Polyclonal mouse anti-
Histone H3 antibody was used as a loading control. Molecular markers
are indicated. (B) Total RNA was extracted from the same cells and SYT/
SSX1-specific message was measured by real time PCR using primers
SYT-SSX1181-1201 F and SYT-SSX1239-1257 R and the universal
probelibrary 76. Quantitation of target RNA, normalized with an
endogenous control (Cyclophilin), was performed using the absolute
quantitation method (Applied Biosystems). Experiments were done in
triplicate. Mean values+/2SD are shown.
doi:10.1371/journal.pone.0007904.g001
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Despite numerous studies, MSCs are still ill-defined with respect
to their physical, phenotypic and functional properties [46,47].
The four independent hMSC populations used in the present
study were isolated and cultured according to standard protocols
and displayed homogeneity for expression of the handful of
standard markers used for their isolation. Nevertheless they were
derived from donors of different ages, albeit all younger than 16
Table 1. List of genes (gene symbols), induced or repressed in human MSCs by SYT-SSX1 expression, belonging to selected
categories or GO terms.
GENES WITH CpGs IN THE TSS
CHROMATIN
ASSOCIATED
GENES
IMPRINTED
(experimentally
confirmed)
IMPRINTED
(all)
CENTRAL
NERVOUS SYSTEM
DEVELOPMENT
GO:0007417
NERVOUS
SYSTEM
DEVELOPMENT
GO:0007399
induced repressed induced Induced induced induced induced
expected
number
52.6 18.5 1.6 0.2 0.7 1.16 3.26
observed
number
65 13 4 5 10 8 14
P value 0.0051 0.98 0.083 1.60E-06 1.60E-09 2.22E-05 4.29E-06
** * * *
ABAT ICAM1 ASPM HIST1H2BG CDKN1C CDKN1C HES1 GPM6B
APCDD1 IGF2 C10orf54 HIST1H4I DIRAS3 COL9A3 FGFR3 INA
AQP3 INA CDC20 LEF1 DLK1 DIRAS3 BMP2 HES1
BMP2 ITGA9 CDKN3 SOX8 H19 DLK1 SOX8 KCNQ2
CABP7 KCNJ2 COL12A1 IGF2 H19 NES FGFR3
CDKN1C KCNQ2 FOXM1 HES1 LHX2 BMP2
CLU L1CAM MOXD1 HSPA6 LEF1 SOX8
COL9A3 LEF1 PRC1 IGF2 CXCR4 NES
COLEC12 LHX2 SFRP4 SOX8 HEYL
CPLX1 LIFR TK1 SPON2 L1CAM
CRABP2 LIPG USP53 SPON2
CRIP1 LONRF3 VGLL3 LHX2
CRLF1 NES ZNF395 LEF1
CRTAC1 NPTX2 CXCR4
CXCR4 PDK4
D4S234E PGF
DIRAS3 PRKAR2B
DLK1 RASD1
DLL1 RHOU
F2RL1 RPESP
FAM46C S1PR3
FBXL16 SERTAD4
FGFR3 SHISA2
GABBR2 SLC16A6
GJB2 SOX8
GPM6B SPON2
H19 SULF2
HBA1 TLL2
HEYL TNFRSF10D
HOPX TPPP
HOXD1 VAT1L
HSPA1A ZNF711
HSPA6
Statistical analysis for the over-representation of each category is reported.
Significant P-values (P,0.05) are marked by an asterisk.
doi:10.1371/journal.pone.0007904.t001
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excluded. We therefore compared the effect of SYT-SSX
expression in the different hMSC populations.
We first performed statistical analysis of transcriptome changes
induced by SYT-SSX1 in each of the four different MSC isolates
and found batch-related variability in the transcription profiles
with some genes affected in some of the batches but not in others
and the same genes affected to varying degrees among the batches.
Complete lists of genes affected by SYT-SSX1 in each single
MSCs batch are reported in table S2. Among the genes that were
affected in some populations but not in others several have been
shown to be related to SYT-SSX expression in other studies
[35,48,49].
Ephrins provide one example of cell batch-dependent gene
regulation by SYT-SSX. Several ephrin receptor/ephrin pathway
components, including ephrin receptors A4, A8, B2 and B3 and
ephrins B1, A3 and A4 have been recently shown to be induced by
SYT-SSX2 in NIH3T3 and other cell lines of mesenchymal and
epithelial origin [35]. We observed a broad induction of ephrins
and ephrin receptors in only a single hMSC population (batch 4),
where ephrins A1 and B3 and ephrin receptors B1, A4 and A3
were induced by SYT-SSX1. Among the other hMSC popula-
tions, ephrin B2 was repressed in 2 batches (1 and 3) while ephrin
receptor B1 was induced in batches 3 and 4 but not in the other 2
batches. Similarly, BCL2, one of the genes whose overexpression
has even been suggested to constitute a molecular marker of
synovial sarcoma [48,49], was induced in two batches of MSCs
(batches 2 and 4) but not in the other two. Changes in expression,
as assessed by microarray analysis, of BCL2, EPHA4 and EPHA3
were validated by real time PCR in each MSC population and
confirmed the microarray observations (Figure 2).
Cell population-related gene expression variability was observed
not only for single genes but also for categories of genes that were
found to be affected by SYT-SSX1 expression. Thus, overrepre-
sentation of genes containing GpG islands differed from batch to
batch with some populations showing significant overrepresenta-
tion only among induced (batch 3 and 4) and others showing
highly significant overrepresentation among both induced and
repressed genes (batch 1and 2). Induction of only four of the
chromatin related group of genes was common to all populations
whereas that of most of the others was batch-specific (table S4,
table S5 and table S6).
The imprinted gene class was over-represented in the lists of
induced genes in all four hMSC batches. Batch-dependent
variation was reflected by the significance of the induction,
batches 2 and 4 having lower p values than batches 1 and 3
(table 2). A few imprinted genes were regulated in some
populations only. Thus, MEST was repressed only in batches 1
and 3, DLK1 only in batches 2 and 4, and PEG3 only in batches 1
and 2. Other imprinted genes, such as TPP12 were also regulated
in only a fraction of the populations (2 and 3) but in opposite
directions, being repressed in batch 2 and induced in batch 3.
Global statistical analysis suggests that the experimentally
confirmed imprinted genes affected by SYT-SSX1 in all MSCs
include H19, CDKN1C, DLK1, DIRAS3 and IGF2 but that,
remarkably, most of them (IGF2, H19, CDKN1C and DLK1) show
different expression profiles in the four cell batches, namely, strong
induction in batch 4, more moderate induction in batches 1 and 2
and no induction in batch 3 (Table 3). These observations were
validated by real time PCR for H19 and IGF2 (figure 3).
Single batch gene expression analysis according to Gene
Ontology (GO) annotation, revealed remarkable variation among
the batches (table S3). For example, in the list of genes induced
by SYT-SSX1 in MSCs population 4, the ‘‘nervous system
development’’ GO term was strongly over-represented (Pvalue
10
210) along with several other related terms including, ‘‘neuro-
genesis’’, ‘‘neuron development’’, ‘‘neuron differentiation’’, ‘‘neu-
rite development’’, ‘‘ephrin receptor activity’’, ‘‘axonogenesis’’,
‘‘cell morphogenesis involved in neuron differentiation’’ and
Figure 2. Induction by SYT-SSX1 of BCL2, EPHA3 and EPHA4
transcripts in four human MSC populations. Histogram represen-
tation changes in the expression of BCL2, EPHA3 and EPHA4 transcripts.
Data are normalized to Cyclophilin, and a comparative Ct method was
used for the analysis. All experiments were done in triplicate. Mean
values+/2SD are shown.
doi:10.1371/journal.pone.0007904.g002
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25). The GO term
‘‘nervous system development’’ was also over-represented in batch
2 (p value 10
29) but not in batch 1 or 3, consistent with SYT-
SSX1-mediated pressure toward neuronal differentiation in some
MSC populations only.
Single population analysis also suggested a variable effect of
SYT-SSX on the expression of genes encoding proteins that
constitute components of the extracellular matrix, mediate cell-
extracellular matrix interactions, and participate in vascular
development, angiogenesis, tissue remodeling and cell motion. In
batch 3, GO term analysis suggests inhibition of expression of
these genes. Similarly, in batch 1, the list of repressed genes
included over-representation of the GO terms ‘‘extracellular
matrix’’, ‘‘extracellular region’’, ‘‘proteinaceous extracellular
matrix’’, ‘‘cell adhesion’’, ‘‘integrin complex’’, ‘‘integrin-mediated
signaling pathway’’. By contrast, in batches 2 and 4, the GO terms
‘‘cell adhesion’’and ‘‘extracellular matrix’’ were over-represented
in the list of induced genes. Expression of these categories of
proteins is important for the biological function of both normal
and cancer stem cells, the former requiring release from their
niche in the bone marrow in order to be recruited to target tissues
where they undergo in situ differentiation and contribute to tissue
regeneration [50], the latter using similar mechanisms to
disseminate and form metastases. CXCR4 and integrins are
among the main effectors of these functions, and induction of
CXCR4 was observed in populations 2 and 4.
Table 2. Lists of imprinted genes (gene symbols), induced or repressed by SYT-SSX1 expression in four independent MSC
populations.
MSC Batch 1 MSC Batch 2 MSC Batch 3 MSC Batch 4
induced repressed induced repressed induced repressed induced repressed
IMPRINTED (experimentally
confirmed)
expected number 1 1.2 0.4 0.5 0.9 0.7 0.6
observed number 4 2 5 1 1 1 4 0
P value 0.015 0.34 5.10E-05 4.20E-01 0.6 0.49 0.0024
* **
DIRAS3 MEG CDKN1C TFPI2 TFP12 MEST CDKN1C
IGF2 MEST DLK1 DLK1
PEG3 H19 H19
SNRPN IGF2 IGF2
PEG3
MSCs Batch 1 MSCs Batch 2 MSCs Batch 3 MSCs Batch 4
induced repressed induced repressed induced repressed induced repressed
IMPRINTED (all) expected number 3.3 4.1 1.4 1.9 3.2 2.3 1.9
found number 11 4 11 4 8 1 8 0
P value 0.00051 0.59 1.70E-07 1.20E-01 0.014 0.9 0.00077
** * *
COL9A3 MEG CDKN1C C20orf82 COL9A3 MEST CDKN1C
DIRAS3 MEST COL9A3 IFITM1 E2F7 COL9A3
HES1 PHPT1 DLK1 PRDM16 FOXF1 DLK1
HOXA3 ZFP36L2 H19 TFPI2 HES1 H19
HOXB3 HES1 HSPA6 HES1
HSPA6 HOXB2 SOX8 IGF2
IGF2 HOXB3 TFPI2 SOX8
PEG3 IGF2 WDR8 SPON2
SNRPN PEG3
SOX8 SOX8
ZNF738 SPON2
Statistical analysis for the over-representation is reported. Data refer to the geneimprint datasets limited to the experimentally confirmed or inclusive of predicted
imprinted genes (all). Significant P values (P,0.05) are marked by an asterisk.
doi:10.1371/journal.pone.0007904.t002
Table 3. SYT-SSX1 induced fold change (log2) of imprinted
genes expression in various hMSC populations.
MSC Batch
1
MSC Batch
2
MSC Batch
3
MSC Batch
4
CDKN1C 0.906 2.407 20.819 1.598
DLK1 0.878 3.486 0.064 3.059
H19(224646_x_at) 0.346 2.153 0.069 5.071
H19(224997_x_at) 0.312 0.534 20.096 4.410
DIRAS3 2.284 0.828 0.769 0.602
IGF2 4.282 3.893 20.354 7.215
doi:10.1371/journal.pone.0007904.t003
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four MSC populations (figure 1), and because each MSC
population was subjected to identical culture conditions when
micorarray analysis was performed, the observed batch-related
variability appeared to be independent of the expression level of
the fusion protein and in vitro culture-related differences. On the
other hand, the observed variability of the response to SYT-SSX
expression did not appear to be random, as suggested by statistical
analysis. Based on this notion, we hypothesized that the qualitative
or quantitative variations in expression of the type and number of
genes in general and within each specific category, could be
attributed to differences in the initial status of each single hMSC
population at the time of fusion gene introduction. These putative
differences in status may determine the effect of SYT-SSX1 and
may consist of epigenetic variations, possibly linked to individual
traits that may be donor age and/or environmental factor-
dependent.
Comparison of the hMSC
SYT-SSX1 Transcriptome with that
of Embryonic Stem Cells and Signatures of Multiple
Pathways Associated with Stemness
To address a possible role of SYT-SSX1 in affecting hMSC
plasticity and stemness, we computed the overlap between the lists
of differentially expressed genes with recently published lists of
stemness markers [51,52]. The analysis was performed using
Figure 3. Baseline and SYT-SSX1- induced H19 and Igf2 RNA expression in the four populations of human MSC. (A) Baseline H19 and
IGF2 RNA expression. Quantitative RT-PCR analysis was performed as described in materials and methods on cDNA samples obtained from each of
the four populations of human MSC. A Taqman probe was used for H19 and hIGF2exon8 F and hIGF2exon9 R primers together with universal
probelibrary 60 were used to test all IGF2 transcripts. Quantitation of target RNA, normalized to an endogenous control (Cyclophilin), was performed
using the absolute quantitation method (Applied Biosystems). Results, reported on a logarithmic scale, are representative of 3 independent
experiments. Error bars reflect results of triplicate PCR tests. (B and C) SYT-SSX1-mediated induction of H19 and IGF2 messenger RNA. Quantitative RT-
PCR analysis was performed as in (A) on cDNA samples obtained from each of the four populations of human MSC infected with SYT-SSX1 or an
empty pMSCV neo vector and selected for 12 days with 0.5 mg/ml of G418.
doi:10.1371/journal.pone.0007904.g003
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multiple « stemness » pathways, including polycomb regulated
genes, target genes of Nanog, Oct4, Sox2 and c-Myc, and target genes
of the RNA binding protein Nanos (NOS). Both lists derived from
the analysis of the four hMSC population together and lists
derived from single population analysis were used, (table S7). No
significant over-representation of Nanog, Oct4, Sox2, c-Myc and NOS
target genes was observed in either analysis and only limited
similarity to the embryonic stem cell signature was noted. By
contrast, polycomb target genes appeared to be affected by the
expression of SYT-SSX1. When using lists obtained by analysing
the four hMSC batches together, a significant over-representation
of polycomb target genes was observed among SYT-SSX1-
induced but not among SYT-SSX1-repressed genes; higher
significance was observed uon analysis of Suz12 target genes
(p value of 10–12).
In single population analysis, overrepresentation of polycomb
target genes was found among the lists of SYT-SSX1-induced
genes in all four hMSC populations. Nevertheless some batch-
dependent variability was observed. Thus, batch 4 displayed a
highly significant (p value 10–20) over-representation of polycomb
target genes in the lists of SYT-SSX1-induced genes but no over-
representation in the lists of SYT-SSX1-repressed genes. Other
batches disclosed less significant over-representation of polycomb
target genes in the lists of SYT-SSX1-induced genes, but batch 3
revealed significant polycomb target gene over-representation in
the lists of SYT-SSX1 repressed genes.
Taken together these data suggest that SYT-SSX1 in plurip-
otent cells may participate in the induction/maintainance of
stemness features by modulating polycomb activity. They support
recent findings that demostrate deregulation of polycomb activity
by SYT-SSX2 in the U2OS cell line [53].
Comparison of the hMSC
SYT-SSX1 Transcriptome with
Sarcoma Gene Expression Signatures
To address possible similarities between the gene expression
profiles induced by SYT-SSX1 in hMSCs and those observed in
sarcomas, we computed the overlap of the lists of differentially
expressed genes with the sarcoma signatures identified in a recent
study [23]. Both the list derived from analysis of the 4 batches
together and lists derived from single batch analysis were used and
the results are summarized in tables (table S8).
Comparison of the lists of both repressed and induced genes
derived from analysis of the 4 batches together revealed a significant
overlap with the reported synovial sarcoma signature (p value about
10
23). A significant overlap was also found with genes repressed in
fibrosarcomas and those induced in gastrointestinal stromal tumors
(GISTs). However, the synovial sarcoma signature was the only one
that displayed overlapwith hMSC
SYT-SSX1lists of both induced and
repressed genes.
Interestingly, comparison of single batches resulted, in the case
of 3 out of the 4 hMSC populations, in enhanced similarity with
the synovial sarcoma signature. Thus, the gene expression profile
of batch 4 overlapped significantly (p,10
27) with both induced
and repressed synovial sarcoma gene signatures, whereas that of
batch 3 overlapped significantly with the list of repressed
(p,10
216) but not with that of induced SS genes.
Common genes comprised transcripts belonging to the
imprinted class, including IGF2, DLK1, PEG3 (in some batches),
chromatin related genes, including histone clusters, genes with
GpG islands within the transcription start site, such as KNNQ2 and
CXCR4, and genes that could play a relevant role in tumor
progression and survival such as BCL2.
Taken together, these data suggest that MSC provide a cellular
context that permits SYT-SSX to induce a transcriptional profile
similar to the one that characterizes synovial sarcoma but that
among individual MSC populations, some are more permissive
than others for these transcriptional changes. Among the observed
transcriptional changes, those involving IGF2, appear to be
particularly relevant in view of both their behavior in different
hMSC isolates in response to SYT-SSX expression (fig. 3 and
table 3) and the recognized role of IGF2 in the initiation and
progression of several types of sarcoma. We therefore analyzed in
detail baseline IGF2 and H19 expression and the corresponding
expression changes induced by SYT-SSX1 in the four hMSC
populations.
Baseline and Allele-Specific H19/IGF2 Expression in hMSC
Multiple transcripts of IGF2 are produced as a result of alternate
promoter usage and splicing: promoter P2-P4-dependent tran-
scripts do not contain exons 1–3, which are incorporated in P1
promoter-dependent counterparts. Promoter P0, on the other
hand, drives expression of transcripts that include exon 3 but not
exons 1 and 2 [54].
Real time PCR experiments were performed using a panel of
different primer/probe sets to assess the expression of several
different IGF2 transcripts and showed that both P1 and P2–P4
driven transcripts were expressed in all the four MSC populations
(data not shown). Absolute quantification (shown on a logarithmic
scale in figure 3A) of H19 and IGF2, using primers encompassing
exons 8 and 9 (all transcripts), revealed higher expression of H19
than IGF2 in all four populations of hMSC. However, the baseline
expression level of each of the two genes varied from batch to
batch (figure 3B,C). Batch 4 had the lowest level of IGF2, about 6
fold lower than batch 1, 10 fold lower than batch 2 and about 500
fold lower than batch 3. H19 transcripts displayed a very similar
profile, with the highest and lowest expression in batches 3 and 4,
respectively.
These observed differences in the basal expression level of IGF2
suggest that the populations of hMSCs may have a different
methylation status at the H19/IGF2 ICR, possibly resulting in
mono-allelic expression in some cases and bi-allelic expression in
others. To test this hypothesis differential allelic expression analysis
was performed by RT-PCR and subsequent restriction fragment
length polymorphism (RFLP). A known polymorphic NarI site at
position 114671 of the human IGF2 gene was analyzed and two (4
and 1) of the four MSC populations were found to be informative
(figure S2). As hypothesized, monoallelic expression of IGF2 was
observed in MSC population 4 (figure 4 and figure S2) whereas bi-
allelic expression was observed in population 1 (figure S2).
Allele-Specific H19/IGF2 Expression Changes Induced by
SYT-SSX1 in hMSC
Real time PCR assessment of the effect of SYT-SSX1 on IGF2
and H19 expression, revealed that 3 out of 4 hMSC populations
displayed strong induction of both messages (figure 3B and C).
The effect of SYT-SSX1 was inversely proportional to the baseline
expression level of the two genes prior to infection: the lower their
baseline expression level, the stronger was the induction by SYT-
SSX. In cells with the highest H19 and IGF2 expression (batch 3),
SYT-SSX1 introduction had no further expression inducing effect
on either gene. These data were consistent with observations made
using Affymetrix micorarrays (table 3) and correlated with the
different degrees of induction of both IGF2 and H19 transcripts as
quantified by real time PCR, ranging from 60–80 fold (batch 1and
2) to 600–700 fold (batch 4). Induction of IGF2 transcripts by
SYT-SSX1 within each cell population was comparable when
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PLoS ONE | www.plosone.org 8 November 2009 | Volume 4 | Issue 11 | e7904Figure 4. Differential IGF2 allelic expression in hMSC population 4 and allele specific IGF2 induction by SYT-SSX1. Differential allelic
expression was investigated by RT-PCR and subsequent restriction fragment length polymorphism (RFLP). A known C/T single nucleotide
polymorphism at position 114671 of the human IGF2 gene (NCBI AC132217) (rs2230949) for which this population was informative, was analyzed. (A)
Genotype analysis: genomic DNA was extracted from hMSC population 4 infected with SYT-SSX or an empty pMSCV neo vector and from a clone of
HEK-293 cell line (293-0). A 237 bp fragment spanning the C/T NarI polymorphic site was amplified using NarI forward and NarI reverse primers. A
heterozygous profile at this position produces fragments of 182 bp (visible on the gel) and 55 bp (not visible on the gel, from the allele carrying a C)
and an undigested fragment (from the allele carrying a T). Digestion efficiency was controlled by a parallel digestion on the same fragment derived
from 293/0 cell lines which show an homozygous profile with both alleles carrying a T at this site. (B) IGF2 expression: A RNA-specific 487 bp
fragment, spanning the IGF2 C/T polymorphism was amplified from hMSC population 4 infected with SYT-SSX or an empty pMSCV neo vector, by
quantitative RT-PCR using cross intron primers Ex8 forward and NarI reverse. Primers amplifying a human bactin fragment were used as a template
control. The 487 bp bands were separated on a 1.5% agarose gel and, after purification, either used for RFLP analysis shown in C) or as a template for
a nested quantitative PCR using NarI forward and NarI reverse primers that produce a 237 bp amplicon. (C and D) NarI restriction digestion profiling
of the 487 bp fragment (C) and of the 237 bp fragment (D) obtained as described in B The schematic representation shows the position of the 2 NarI
sites (vertical lanes) and the position of the primers used (arrows). The heterozygous profile shown at both sites is the only one consistent with the
generation of the 3 bands at 305, 244/243 and 182 bp, observed by NarI digestion, given the heterozygosity for the NarI site at position 114671
(shown in A). DNA fragments were incubated at 37uC for 3 hrs in the appropriate digestion buffer with or without 4 U of NarI. Fragment size analysis
was performed on a 2% agarose gel, first lane of each gel shows Lambda DNA/BstE II Digest marker, fragment size is indicated. C) Bands of 305 and
182 bp are derived from one allele, whereas 244/243 bp bands are derived from the other allele; the heteroduplex undigested PCR product is also
shown. D) In the 487 bp fragment, the heterozygous profile at position 114671 of the IGF2 gene produces 3 fragments: a 182 bp (visible on the gel)
and a 55 bp (not visible on gel) derived from the allele carryng a G at this position and the undigested fragment derived from the other allele or from
the heteroduplex product. The differential intensity of the bands shows that induction of IGF2 by SYT-SSX1 involves both alleles.
doi:10.1371/journal.pone.0007904.g004
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selected. No intra-population transcript discrepancies were
observed (data not shown).
Assessment of results obtained on the induction of IGF2 limited
to batch 4 is consistent with a SYT-SSX-mediated switch from
mono-allelic to bi-allelic expression according to the shared
enhancer model, suggesting that, in these cells, the fusion may
have a selective effect on the silent allele. To verify this notion, we
tested allelic IGF2 expression changes induced by SYT-SSX in
hMSC population 4, which contained the polymorphic NarI site
in the IGF2 coding sequence (figure 4A.). SYT-SSX1-induced
upregulation of IGF2 expression was measured by semi-quantita-
tive-RT-PCR and subsequent RFLP analysis using primers
corresponding to sequences located in exon 8 and 9 and spanning
two NarI polymorphic sites (Figure 4B). To analyze allele specific
induction, taking into account heteroduplex formation and ruling
out DNA contamination, we performed RFLP analysis on both
the first amplicon containing two polymorphic NarI sites (fig. 4C)
and on a second fragment containing only one polymorphic site
(fig. 4D). In both cases restriction fragment analysis showed that
hMSC population 4 expressed IGF2 from only a single allele and
that introduction of the fusion gene induced expression of the
silent allele. Nevertheless, we also observed a significant, SYT-
SSX1-dependent increase in the activity of the active allele, since
the 244/243 bp bands derived from digestion of this allele were
more intense in SYT-SSX1-expressing cells than in cells infected
with an empty vector (figure 4C). This was also visible in figure 4D
(237 bp undigested bands) although, in this case the possible
presence of undigested heteroduplexes must be taken into account.
These observations demonstrate that SYT-SSX1 can induce
loss of imprinting in cells that show an intact imprinted status at
the H19/IGF2 locus. On the other hand, the observation that, in
batch 4, the activity of the non silent allele can also be increased by
SYT-SSX1 supports the notion that additional mechanisms are
involved in the induction of IGF2, at least in some hMSCs.
Allele Specific Methylation
To gain insight into the mechanism(s) whereby SYT-SSX might
induce IGF2 in different hMSC populations, we compared the
DNA methylation status twelve days following infection with SYT-
SSX1 or empty vector. We first analyzed a region in the H19 ICR
(AF125183: 7712–8192), including the sixth CTCF binding site
(figure 5) that has been suggested to be a key regulatory domain for
switching between H19 and IGF2 expression. It is the only out of 7
binding sites in the human ICR that has been demonstrated to
have allele specific methylation in normal human embryonic
ureteral tissue [55] and been shown to be hypomethylated in
human bladder cancer and some osteosarcomas [55,56], but
hypermethylated in Wilms’ tumor and colon cancer [57].
We first tested DNA from non transformed cells for the
presence of polymorphic sites in this region by direct sequencing of
PCR products obtained using different combinations of the
following forward and reverse primers: H19- 7712Fw, H19-
8192R, H19-7565Fw, H19-8298R and H19-7895R. Three
polymorphic sites are known to exist within this region
(rs10732516) (rs2071094) (rs2107425). DNA extracted from our
four hMSC populations did not show double peaks at position
7966 (rs10732516) or at position 8008 (rs2071094). However,
hMSC populations 1, 3 and 4 displayed a double G/A peak at
position 8097 (fig. S3C) whereas population 2 showed a single
peak (not shown).This SNP (rs2107425) affects an NlaIII
restriction site (fig. S3A) and we used restriction fragment length
polymorphism (RFLP) analysis to determine heterozygosity.
Following NlaIII digestion of the specific PCR product obtained
from each of the 3 MSC populations, we observed a heterozygous
profile consisting of 2 fragments of 215 bp (from the allele
containing a G) and 296 bp (from the allele containing an A) in
addition to common fragments of 81, 87 (comigrating) and 17 bp
(not visible on the gel, fig. S3B). Bisulfite transformation analysis,
based on the presence of this polymorphic site, allowed assessment,
in populations 1, 3 and 4, of allele-specific methylation at the 26
CpGs included in the region amplified by primers BS-7712sense
and BS-8192antisense. In population 2 only a general assessment
without allelic distinction was made.
The methylation status we found at this region was highly
divergent from population to population: MSC batch 4 was the
only one that showed an intact imprinting status with an overall
methylation of 83% on one allele and 4.6% on the other (table 4).
Populations 1 and 3 displayed a profile compatible with loss of
imprinting, with no major allele-specific difference in methylation
and a much lower overall methylation (around 4–6%). Although
we could not discriminate between the two alleles in population 2,
the overall methylation in this region was substantially lower than
in batch 4 (6.4% versus 44%). Even when the closely apposed
CpGs that constitute the putative sixth CTCF binding site (CpGs
7–11 in figure 5) are considered, only batch 4 showed allelic
specific methylation. In all the other batches methylation of this
region was lower without significant difference between alleles.
These data correlate with those obtained by measuring IGF2
expression by RT-PCR although they cannot explain the H19
expression pattern. The lower level of IGF2 in population 4 is
compatible with monoallelic expression observed by RFLP
analysis that can be explained by differential DNA methylation
according to the shared enhancer model. Conversely, in
populations 1, 2 and 3, the higher baseline IGF2 expression level
could be explained by bi-allelic expression derived from an almost
un-methylated status on both alleles at the sixth CTCF binding
site. Bi-allelic IGF2 expression was confirmed in population 1 by
RFLP.
The last three CpGs included in our amplicon (CpGs 23–26 in
figure 5) seemed to constitute a separate region in these cells and
batch 1 and 3 displayed allele-specific differential methylation only
at these sites (figure 5). In batch 4 they show conformity with the
other CpGs regarding the imprinting status (1–23) but appeared
more heavily methylated.
Although these last residues were not clearly readable in all of
the sequenced clones (missing residues in figure 5) the number of
clones in which they were determined is sufficient to reveal the
higher methylation and the allelic distinction.
Allele Specific Methylation Changes Induced by SYT-SSX1
We next compared the methylation pattern of the same H19
IRC, including that 6
th CTCF binding site, among all four hMSC
populations twelve days following infection with SYT-SSX1-
containing retrovirus or an empty vector. Expression of SYT-
SSX1 in population 4 resulted in modest hypermethylation, the
effect being more marked on the methylated (paternal) allele (from
83% to 88% methylation when all 26 CpGs were included
(Table 4)) than on the maternal un-methylated allele (from 4.6% to
6.8% when all 26 CpGs were considered (Table 4)). This
magnitude of variation is similar to that shown by others in
HEK- 293 cells [11]. Interestingly, the observed increase in
methylation by SYT-SSX1 was limited to the first 23 CpGs and
this was particularly the case on the maternal allele (%methylation
rises from 1% to 3.3% when CpGs 1–23 only are included). By
contrast, at the last three CpGs, SYT-SSX1 expression produced
the opposite effect, with considerable hypomethylation on both
alleles.
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PLoS ONE | www.plosone.org 10 November 2009 | Volume 4 | Issue 11 | e7904Figure 5. Methylation profile as determined by bisulfite transformation analysis at the H19 ICR region amplified by primers
BS-7712sense and BS-8192antisense in different human MSC populations. Each line represents one cloned segment; the 26 individual
CpGs (circles) are numbered 1–26. Clones derived from each allele are grouped and indicated. White circles represent un-methylated and black circles
methylated CpGs.
doi:10.1371/journal.pone.0007904.g005
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limited to one allele at CpGs 1–23 accompanied by considerable
hypomethylation at residues 23–26 on both alleles was also
observed. In batch 2 we could not see any change in methylation
at positions 1–23, which may be due to compensation between the
two alleles that could not be distinguished in these cells. In either
case, strong hypomethylation was observed at CpG sites 23–26.
Finally, population 3 showed a slight increase in methylation on
one allele (from 9% to 12%) when the entire region was assessed
that was attributable not to hypermethylation of the first 23 CpGs,
which remained unchanged on both alleles, but, contrary to the
other populations, to hyper-methylation of the last three.
Thus, in all 4 populations, residues 1–23 or, more specifically,
residues that correspond to the sixth CTCF binding site (CpGs 7–11
table 4) displayed the same trend in response to SYT-SSX1
expression. In this regard therefore, population 3, the only population
in which SYT/SSX1 did not induce IGF2 was also the only one in
which the fusion did not induce an increase in methylation at the
insulator binding site. Nevertheless, SYT-SSX1 significantly affected
methylation of CpGs 23–26 in this population but in the opposite
direction to that observed in the other populations.
We also assessed, by bisulfite transformation analysis, the
methylation changes induced by SYT-SSX1 in a second region
located outside the H19 ICR (figure 6). This region, amplified by
primers BS-13212sense and BS-13548antisense, was included in a
CpG island located 39 to the H19 gene. Fifteen CpG sites were
analyzed within this region. Allelic discrimination was possible in
batches 1 and 4, which had a C/A polymorphism at position
13359 (rs 217133) (batch 4) and a C/G polymorphism at position
13270 (batch 1). Allele-specific differential methylation was also
observed in this region although not as markedly as in the ICR
(76% on one allele and 40% on the other in batch 1; 87% on one
allele and 67% on the other in batch 4) (table 5).
The effect of SYT-SSX1 introduction varied from batch to
batch. Strong hypomethylation was induced in batch 3 (from 67%
to 11%) whereas batch 1 and 4 showed significant hypermethyla-
tion. This increase in methylation involved both alleles in batch 1
but was limited to only one allele (the one less methylated) in batch
4.
Discussion
We have analyzed the transcriptional effects of SYT-SSX1
expression in bone marrow derived human mesenchymal stem
cells isolated from pediatric or adolescent patients. These cells may
provide an appropriate model to study synovial sarcoma
development, based on the generally recognized notion that SS
originates from as yet unidentified pluripotent stem cells capable of
mesenchymal and neuroectodermal differentiation. The only
available transgenic model of SS [14] thus far, suggests that
development of SS is linked to the expression of the early
myogenic marker Myf5. Co-expression of early markers for
different tissue lineages has been observed in MSCs [58], without
necessarily being associated with loss of plasticity. Human MSC
expressed Myf5 with up to a 30-fold population-dependent
transcript level variation (data not shown). However, we could
not establish whether the observed differences in expression were
due to varying enrichment of a specific sub-population or to
homogeneous, donor specific, traits.
Human MSC
SYT-SSX1 display a transcriptional profile with
significant similarity to the gene expression signature of synovial
sarcoma, supporting the notion that these cells could have features
common to the pluripotent mesenchymal cell of origin of SS.
Analysis of the transcriptional profile of hMSC
SYT-SSX1 revealed
overexpression of genes related to nervous system development,
suggesting that SYT-SSX1 may exert some degree of pressure
toward neuronal differentiation in mesenchymal stem cells.
Several reports [59], including a recent proteomics-based study
[60], have shown a similar gene expression profile among clear cell
sarcoma, synovial sarcoma, and MPNST supporting the assump-
tion that these three tumors may be derived from, or differentiate
toward, neuroectodermal cells. Rare cases of synovial sarcoma,
identified by SYT-SSX expression, have in fact been reported to
express neural immunomarkers [61].
Single population analysis according to Gene Ontology (GO)
annotation revealed remarkable variation among batches. The
observed variation involved single genes whose overexpression has
been associated with synovial sarcoma, including BCL2 and IGF2
as well as clusters of genes implicated in cell trafficking and
differentiation. Thus, some populations of MSC appeared to be
more permissive than others for SYT-SSX-induced changes in the
expression of genes relevant to fundamental requirements for
normal and cancer stem cell biology. Similarly, single population
analysis revealed greater similarity of some MSC
SYT-SSX1
population transcriptomes than others to SS gene expression
signatures, supporting the hypothesis that features which distin-
guish independent hMSC isolates and contribute to their
heterogeneity may be key for SYT-SSX function. Our present
observations suggest that the nature of these putative features may,
at least in part, be epigenetically determined.
Table 4. Percentage of methylated CpGs at the H19 ICR region amplified by primers BS-7712sense and BS-8192antisense in
different human MSC populations.
CpG 1–23 1–23 23–26 23–26 7–11 7–11 1–26 1–26
EMPTY SYT-SSX EMPTY SYT-SSX EMPTY SYT-SSX EMPTY SYT-SSX
Batch 1 allele with A 1% 7.1% 54% 22% 0% 5.7% 4.6% 7.9%
Batch 1 allele with G 4.3% 2.1% 3% 2.9% 5.8% 4.1% 4.2% 2.2%
Batch 2 4.8% 5% 23% 2.6% 6.6% 5.9% 6.4% 5%
Batch 3 allele with A 4.8% 4.5% 61.5% 67% 6.7% 5.2% 9% 12%
Batch 3 allele with G 3.9% 2.4% 7.4% 10.4% 0.7% 1.25% 4.1% 3.4%
Batch 4 allele with A 1% 3.3% 43% 34.5% 1.7% 2.8% 4.6 6.8
Batch 4 allele with G 82% 89% 90% 82% 90% 96% 83% 88%
Specific alleles are indicated.
doi:10.1371/journal.pone.0007904.t004
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SYT-SSX1 showed that a major
effect of SYT-SSX in hMSCs involves changes in the expression of
epigenetically regulated genes, including imprinted genes, genes
that contain CpG island in their TSS and chromatin related genes.
Epigenetic de-regulation has been suggested to be a central effect
of the aberrant expression of SYT-SSX and a possible mechanism
underlying synovial sarcoma formation. The present transcrip-
tome analysis of hMSC expressing SYT-SSX strongly supports
this notion.
Consistent with the variability of MSC
SYT-SSX1 transcriptome
relatedness to SS signatures and that of GO term overrepresentation,
single population analysis limited to datasets of epigenetically
regulated genes showed marked qualitative and quantitative differ-
ences among the four hMSC isolates, the most striking being the
divergent effect of SYT-SSX on the expression of imprinted genes. It
is therefore conceivable that epigenetic features displayed only by
some hMSC populations permit SYT-SSX to affect expression of
genes implicated in biological functions relevant to stem cells and SS.
We therefore sought divergent epigenetic characteristics among the
MSC populations that may explain the significant variations observed
in the transcriptional effect of SYT-SSX.
Assessment of the H19/IGF2 cluster provided support for our
hypothesis. IGF2 is considered to be one of the signature genes of
SS and is part of one of the best characterized imprinted clusters.
Deregulation of its expression has been suggested to play a role in
the development of several types of cancer. Real time PCR
Figure 6. Methylation profile as determined by bisulfite transformation analysis in the region amplified by primers BS-13212sense
and BS-13548 in different human MSC populations. Each line represents one cloned segment, the 15 individual CpGs (circles) are numbered
1–15. Clones derived from each allele are grouped and indicated. White circles represent un-methylated and black circles methylated CpGs.
doi:10.1371/journal.pone.0007904.g006
Table 5. Percentage of methylated CpGs in the region
amplified by primers BS-13212sense and BS-13548 antisense
in different human MSC populations.
CpG position 1–15 1–15
EMPTY SYT-SSX
Batch 1 allele with G 76.6% 86%
Batch 1 allele with C 40% 52%
Batch 2 67% 11.6%
Batch 4 allele with A 67.4% 78%
Batch 4 allele with G 87% 84.8%
Specific alleles are indicated.
doi:10.1371/journal.pone.0007904.t005
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variable levels of IGF2 and H19 transcripts. Although a complex
network of long range interactions and multiple looping are
emerging as newly recognized regulators of H19 and IGF2 [37,38],
the methylation status at the H19 imprinting control region (ICR)
remains a basic regulatory factor according to the shared enhancer
model. Bisulfite transformation analysis revealed a highly diver-
gent methylation pattern among hMSC populations both at the
H19 ICR and in a second region downstream of the H19 gene. In
those populations that were found to be informative, the
methylation pattern at the H19 ICR was shown to be compatible
with maintenance or loss of imprinting and to correlate
accordingly with a mono or bi-allelic IGF2 expression that could
explain, at least in part, the different level of mRNA measured by
RT-PCR. Thus different hMSC populations displayed a different
imprinting status at the H19/IGF2 ICR. Epigenetic variation,
which could be a function of numerous factors, including age and
environmental conditions, has been shown to characterize
stem cells and to play an important role in determining cell
commitment and plasticity [62–64]. Consistent with this notion,
the cells used in the present study were derived from different
donors whose age variation, although in the pediatric/adolescent
range, could conceivably explain, at least in part, their distinct
epigenetic features.
Expression of SYT-SSX in the four populations produced
variable epigenetic effects.
Methylation analysis at the H19 ICR showed modest changes,
hypermethylation on both alleles being induced by SYT-SSX in
only one population whereas other populations displayed either no
effect or opposite effects on the two alleles. The absence of
methylation changes in population 3 can be reconciled with the
observed absence of induction of IGF2 expression. Conversely in
population 4 the hypermethylating effect of SYT-SSX at the 6
th
CTCF binding site may explain, in part, the induction of the IGF2
transcripts. The observed SYT-SSX-dependent switch from
monoallelic to biallelic expression of IGF2 in this population,
together with the methylation changes, is consistent with SYT-
SSX-induced LOI according to the shared enhancer model.
Hypermethylation of both alleles in these cells can also explain the
observation that, in addition to the re-expression of the silent
allele, expression of the active allele was increased.
In population 1, where a methylation pattern consistent with
loss of imprinting and a corresponding baseline bi-allelic IGF2
expression were demonstrated, the effect of SYT-SSX at the 6
th
CTCF binding site produced modest but opposite effects on the
two alleles. SYT-SSX1-mediated enhancement of IGF2 and H19
expression in this population must therefore have been achieved
by alternative mechanisms since it cannot be explained by the
reactivation of a silent allele. The involvement of alternative and/
or additional regulatory factors at the H19/IGF2 locus that may be
directly or indirectly affected by SYT-SSX expression is suggested
by several observations emerging from the present study.
Concomitant induction of H19 observed in all cases is not
compatible with the sole perturbation by SYT-SSX1 of ICR
imprinting. Furthermore the similar activation of both P1 and
P2–P4 IGF2 promoters is also suggestive of the existence of
multiple regulatory mechanisms affected by the fusion protein
since several independent observations suggest that not all IGF2
promoters are regulated exclusively by the imprinting control
region. It has been reported that in hepatocytes and chondrocytes,
IGF2 transcripts from promoter P1 are derived from both parental
alleles, whereas transcripts from promoters P2, P3 and P4 are
derived from a single parental allele [65]. These observations
suggest that P1 promoter activity could be at least partly
independent of the ICR. It is noteworthy that the P1 transcript
is reported to be expressed from both parental alleles in postnatal
liver and fetal choroid plexus/leptomeninges [66], and that P1
promoter activity was observed not to be exclusively connected to
IGF2 LOI in laryngeal squamous cell carcinoma [67].
Methylation analysis of regions outside the H19 ICR showed
that SYT-SSX1 does not affect methylation specifically and
exclusively at the H19 ICR but rather at different discrete regions
with even opposite effects in adjacent segments and in different
hMSC populations. The exact mechanism whereby SYT-SSX
affects methylation and possibly the complex network of long
range interactions and multiple looping that regulate the H19/
IGF2 locus remains to be defined. Our data suggest that a specific
epigenetic substrate, defined by a normal imprinting status and
monoallelic expression of IGF2 are required for a strong effect of
SYT-SSX on IGF2 expression and that changes in the baseline
epigenetic status, can prevent SYT-SSX1 from exerting its effect
on the H19 ICR. On the other hand our data also suggest that the
effect of SYT-SSX is not limited to methylation changes at the
H19 ICR but rather affects additional, hitherto undefined,
regulatory mechanisms at the H19/IGF2 locus.
We have shown that introduction of SYT-SSX into different
populations of hMSC has effects on epigenetic function that
display cell-type specific qualitative and quantitative variation. We
hypothesize that this variation could originate from the differences
in the epigenetic context that the fusion protein encounters and
that minor baseline epigenetic changes may have a relevant
bearing on SYT-SSX function. It is possible that a highly specific
epigenetic status is required for transformation of primary cells by
SYT-SSX, which may explain, in part, the low frequency of SS.
Such a permissive epigenetic status may be confined to cells at a
specific stage of differentiation, as suggested by the recently
reported transgenic mouse model.
Materials and Methods
Ethics Statement
Human mesenchymal stem cells were obtained from femoral
head bone marrow of patients undergoing total hip replacement
according to the guidelines of the Ethics Committee protocol
01–172 of the University of Geneva and after written informed
consent of the patients.
Cell Culture
Human mesenchymal stem cells were obtained as previously
described [41,42]. MSCs were cultured at low confluence in
IMDM, 10% FCS, 10 ng/ml PDGF-BB (PeProtechEC, London,
UK) and were tested for multilineage differentiation into
adipocytes, chondrocytes and osteoblasts. Expression of mRNA
encoding Myf5 early myogenic differentiation marker was tested
by real time PCR.
Constructs and cDNA Cloning
cDNA clones, encoding the human SYT-SSX1 fusion gene were
amplified from surgically resected synovial sarcoma tissue by RT-
PCR, using hSYTforward and hSSXreverse primers (without a
stop codon). Tumor specimens were freshly frozen and stored at
280C until use. Total RNA was isolated from frozen tumors using
Trizol reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’s recommendations and RT-PCR was performed
using Super Script one step RT-PCR with the platinum Taq kit
(Invitrogen) under the following cycling conditions: 1 cycle at 50uC
for 30 min, and 94uC for 2 min followed by 30 cycles of 94uC for
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72uC for 10 min.
Amplified fragments were inserted, using the pEF6/V5-His
TOPO TA expression kit (Invitrogen, Carlsbad, CA), into the
corresponding expression vector in frame with the V5 epitope tag.
This construct was used as a template for amplification of a SYT-
SSX-V5 fragment with EcoRIhSYT and V5 reverse primers
(including a stop codon); the resulting fragment was inserted into
the pMSCV Neo retroviral expression vector into the EcoRI and
the HpaI blunt site (BD Biosciences Clontech, Palo Alto, CA) and
construct integrity was verified by sequencing.
Retroviral Infection
Expression of SYT-SSX1-V5 in hMSCs was achieved using
Retroviral Gene Transfer and Expression (BD Biosciences
Clontech) according to the manufacturer’s recommendations.
Expression of the fusion genes and corresponding proteins was
tested in all four batches of cells by real time-PCR and Western
blot analysis using mouse anti-V5 antibody, respectively. Infected
cells were selected with 0.5 mg/mL neomycin for 12 days and the
bulk of the resistant cells was used in subsequent experiments.
Western Blot
Cell lysis, SDS-PAGE and blotting, were done by standard
procedures and protein bands were detected with a chemilumi-
nescent substrate kit (Pierce) according to the manufacturer’s
recommendations. The antibodies used were: mouse anti–V5
monoclonal antibody (Invitrogen), anti–Histone H3 (Abcam),
horseradish peroxidase–conjugated goat anti-mouse IgG (Amer-
sham) and goat anti-rabbit IgG (Biorad).
Real Time Quantitative RT-PCR
cDNA was obtained using an M-MLV reverse transcriptase and
RNAse H minus (Promega). Typically 500 ng of template total
RNA and 250 ng of random hexamers were used per reaction.
Real time-PCR amplification was performed in an ABI Prism
7700 instrument (Applied Biosystems). For P1 promoter tran-
scripts of IGF2, H19 and cyclophilin, Taq Man Universal PCR
mastermix and Assays-On-Demand Taq Man probes were used.
For real time quantitation of SYT-SSX RNA and for
discrimination of IGF2 transcripts, the Universal Probe Library
system (Roche Rotkreuz, Switzerland) was used and primers were
designed according to the ProbeFinder software (http://www.
roche-applied-science.com).
Primers used were as follows: SYT-SSX1-181-1201Fw and
SYT-SSX1-239-1257R were used with universal probelibrary 76.
hIGF2exon8Fw and hIGF2exon9R were used with universal
probelibrary 60 to test the expression of all IGF2 transcripts
including the INS-IGF and those derived from the activity of the P0
promoter.
hIGF2exon6Fw and hIGF2exon7R were used with universal
probelibrary 63 to test the expression of P2–P4 derived IGF2
transcripts. Taq Man probe Hs00171254_m1, spanning exons 1
and 2, was used to test IGF2 expression driven by promoter P1.
Quantitation of target RNA, normalized with an endogenous
control (Cyclophilin), was performed using the absolute quantita-
tion method (Applied Biosystems).
Validation of microarray data relative to BCL2, EPHA4, EPHA3
and MYF5 expression was performed using both the Universal
Probe Library system and sybergreen. Primers designed according
to the ProbeFinder software and the corresponding probelibraries
used are reported in the primers table (table S1). In these cases a
comparative Ct method was used for the analysis.
Affymetrix Microarrays and Bioinformatic Analysis
Total RNA was extracted using an RNeasy Mini Kit
(QIAGEN, Valencia,CA) according to the manufacturer’s recom-
mendations. The quality of total RNA was verified by an Agilent
RNA 600 nanoassay and by measuring the 260/280 absorbance
ratio. The corresponding quality-tested total RNA was used by the
Lausanne DNA Array Facility (DAFL) to perform gene expression
profile analysis on Affymetrix HG-U133 Plus 2.0 Arrays,
according to the manufacturer’s recommendations (http://www.
unil.ch/dafl/). Gene expression levels were obtained with RMA
[68]using the Affymetrix Power Tools suite. Differential expression
for the single batches was determined by requiring a fold-change
greater than 2. Statistical analysis to determine differentially
expressed genes across all the available batches was performed
with Rank Products [69]: genes selected by rank products with a
FDR of 1% or less and with mean fold change greater than 2 were
retained for further analysis. Over representation of various
functional categories, detailed below, was performed by first
translating the lists of differentially coexpressed probesets into lists
of Entrez Gene ids using the annotation files provided by the
manufacturer (version na26), and then performing exact Fisher
tests. Gene Ontology [45] annotations were obtained from Entrez
Gene (data downloaded Oct. 26, 2008). We used version
20081012 of the Gene Ontology. The imprinted genes listed by
Geneimprint (http://www.geneimprint.com) and the Catalogue of
Imprinted Genes at the University of Otago [43] http://igc.otago.
ac.nz were downloaded from the corresponding web sites on Dec.
12th and Nov. 11th 2008, respectively. For the Geneimprint
database we separately considered all predicted imprinted genes
and the experimentally confirmed ones only. Chromatin-associated
proteins were downloaded from the chromdb site [44] url on Nov.
11th, 2008. All gene symbols from these databases were converted
into Entrez Gene ids using the gene_info file obtained from the
Entrez Gene ftp site.
A list of CpG islands in the human genome (sequence version
hg18) was obtained from the UCSC genome browser site url. We
then used the TSS coordinates predicted by UCSC to determine
which transcripts have their TSS lying in such CpG islands. This
list was converted into a list of Entrez gene ids using the conversion
table provided by UCSC.
Sarcoma signatures of reference [23] were obtained from
the manuscript’s supplementary material. Embryonic stem cell
signatures were downloaded from the supplementary material of
reference [51].
Bisulfite Transformation of Genomic DNA
Genomic DNA from MSCs was isolated using a DNeasy Tissue
Kit (Qiagen), and 200 ng of DNA were bisulfite modified using an
EZ DNA Methylation Kit (Zymo Research) according to the
manufacturer’s instructions. About 1/5 of the eluted DNA was
used as template for each PCR reaction.
Cloning and Sequencing of Bisulfite-Treated DNA
Primers used for bisulfite-treated DNA amplification were
designed using the primer design program MSPprimer (http://
www.mspprimer.org/cgi-mspprimer/design.cgi). Primer sequence
is reported in table S1.
Both MSPprimer and Methprimer (http://www.urogene.org/
methprimer/index1.html) were used for in silico sequence analysis
of bisulfite transformed DNA. The region amplified by primers
BS-7712sense and BS-8192 antisense was located in the H19 ICR
and included the sixth CTCF binding site. Twenty-six GpG sites
were analyzed within this amplicon.
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13548antisense was included in a CpG island located about 3 kb
downstream of the H19 TSS, and 15 CpG sites were analyzed
within this amplicon.
Several PCR reactions for the amplification of the H19 ICR or
the H19 gene downstream region from bisulfite treated DNA were
performed and pooled before cloning.
To overcome bias in methylation analysis (we in fact observed
preferential allelic amplification that was annealing temperature–
dependent) [70], we used various annealing temperatures ranging
from 55 to 60uC and employed both Go-taq (Promega) and the
Fusion Taq polymerases (Finnzymes), to allow the use of maximal
annealing temperature. In the latter case the obtained PCR
fragments were purified and subsequently incubated at 70uC for
30 minutes in the presence of Go-Taq DNA polymerase buffer,
0.2 mM dATP and 5 units of Go-Taq DNA polymerase for
subsequent TA cloning.
The following conditions were used for Go-Taq PCR: 95uC5
minutes, 40 cycles 95uC 30 seconds, 55uC 45 seconds, 72uC4 5
seconds and a final extension at 72uC for 7 minutes.
For Fusion Taq polymerase PCR, the conditions were as
follows: 98uC 2 minutes, 40 cycles 98uC 20 seconds, 60uC2 0
seconds, 72uC 45 seconds and a final extension at 72uC for 7
minutes. PCR products of the expected size were separated on
1.5% agarose gel and, after purification, were cloned into the pCR
4-TOPO vector using a TOPO TA Cloning Kit for sequencing
(Invitrogen), and then transformed into Top10 E.Coli. For each
sample the DNA of plasmid from 18 to more than 30 positive
clones was sequenced for methylation analysis. Only clones with
bisulfate conversion efficiency higher than 97% were taken into
account.
Allele Specific Methylation
In the region downstream of the human H19 gene, the following
polymorphic sites were considered (number refer to NCBI
AF125183):
C/A at position 13359 (rs 217133) for which population 4 was
heterozygous
C/G at position 13270 for which population 1 was heterozy-
gous
In the H19 ICR:
the G/A single nucleotide polymorphism at position 8097 for
which populations 1, 3 and 4 were heterozygous.
Heterozygosity for specific polymorphic sites was determined
either by direct sequencing or, when possible, by restriction
fragment length polymorphism (RFLP) of specific PCR fragments.
In the case of the G/A polymorphism at position 8097 a specific
NlaIII restriction site was analyzed. A 481 bp fragment, spanning
the NlaIII polymorphic site, was amplified by PCR from MSC
genomic DNA using primers H19 7712F and H19 8192 R. After
purification on a 1.5% agarose gel the fragment was incubated at
37uC for 3 hrs in the appropriate digestion buffer with or without
10 U of NlaIII. Fragment size analysis was performed on a 2%
agarose gel.
Allelic specific methylation was determined by grouping single
clones according to the relative sequence at the specific
polymorphic sites.
Allelic Expression Analysis of IGF2
Allelic differential expression was assessed by RT-PCR and
subsequent restriction fragment length polymorphism (RFLP). A
known C/T single nucleotide polymorphism (rs2230949) at
position 114671 of the human IGF2 gene (NCBI AC132217), for
which populations 4 and 1 were informative, was analyzed. A
semi-quantitative RT-PCR reaction was performed using super-
script one step RT-PCR platinum Taq kit (Invitrogen) and intron
crossing primers Exon8 F and NarI R. In pilot experiments we
established conditions such that none of the RNAs analyzed
reached a plateau at the end of the amplification protocol.
After separation on a 1.5% gel the 487 bp fragments,
exclusively derived from RNA, were purified and either directly
used for restriction fragment length polymorphism (RFLP) analysis
or for nested semi-quantitative PCR. Digestion of 487 bp
fragments containing two polymorphic NarI sites produced 244/
243 bp fragments from one allele and 305 and 182 bp fragments
from the other. The expected heteroduplexes formed during the
PCR reaction remained undigested. Nested PCR was performed
using primers NarI F and NarI R spanning the polymorphic site,
and the 237 bp fragments obtained were used for RFLP analysis.
Fragments were incubated at 37uC for 3 hrs in the appropriate
digestion buffer with or without 8 U of NarI (NEB). Fragment size
analysis was performed on a 2% agarose gel. Digestion produced a
182 bp fragment from one allele and the undigested form from the
other, or the heteroduplex. Digestion efficiency was controlled by
parallel digestion of similar fragments obtained from homozygous
samples.
Supporting Information
Figure S1 hMSCs differentiation into adipogenic, osteogenic,
and chondrogenic lineages upon stimulation with the appropriate
cytokines. (see Materials and Methods for details). Adipocytic
differentiation, oil Red-O staining; osteoblastic differentiation, von
Kossa staining; and chondrocytic differentiation, anti-collagen
type II labeling counterstained with hematoxylin. Magnification:
adipocytes and osteocytes, _200; chondrocytes, _100.
Found at: doi:10.1371/journal.pone.0007904.s001 (1.55 MB TIF)
Figure S2 Differential Igf2 allelic expression in human mesen-
chymal stem cell population 1 and 4. Allelic differential expression
was investigated by RT-PCR and subsequent restriction fragment
length polymorphism (RFLP). A known C/T single nucleotide
polymorphism at position 114671 of the human Igf2 gene (NCBI
AC132217) (rs2230949) for which these populations were
informative, was analyzed. Genomic DNA and RNA were
extracted from hMSC populations 1 and 4. A 237 bp fragment
spanning the C/T NarI polymorphic site was amplified using NarI
forward and NarI reverse primers from the DNA template. Upon
NarI digestion, heterozygous profile at this position produces
fragments of 182 bp (visible on gel) and 55 bp (not visible on gel)
(from the allele carryng C) and an undigested fragment (from the
allele carryng T). A RNA specific 487 bp fragment, spanning the
Igf2 C/T polymorphism was amplified by quantitative RT-PCR
from RNA extracted from hMSC populations 1 and 4, using cross
intron primers Ex8 forward and NarI reverse. The 487 bp bands
were separated on a 1.5% agarose gel and, after purification, used
as a template for a nested quantitative PCR using primers NarI
forward and NarI reverse that produce the 237 bp amplicon.
DNA fragments were incubated at 37uC for 3 hrs in the
appropriate digestion buffer with or without 4,000 U of NarI.
Fragment size analysis was performed on a 2% agarose gel.
Lambda DNA/BstE II Digest marker were used, fragment size is
indicated.
Found at: doi:10.1371/journal.pone.0007904.s002 (0.07 MB TIF)
Figure S3 Human mesenchymal stem cell populations genotype
analysis. Heterozygosity for the G/A singol nucleotide polymor-
phism at position 8097 of the human H19 gene (NCBI AF125183)
was analysed by restriction fragment length polymorphism (RFLP)
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Numbers are all referred to NCBI AF125183 A) Schematic
representation showing the position of the 4 NlaIII restriction sites
in the H19 gene fragment from 7712 to 8192. The polymorphic
NlaIII site at position 8097 is indicated. Heterozygous profile at
this position produces 2 fragments of 215 bp (from the allele
carryng G) and 296 bp (from the allele carryng A) in addition to
81, 87 and 17 bp common fragments. B) NlaIII restriction
digestion profiling of the H19 gene fragment 7712–8192 obtained
from 3 different Human mesenchymal stem cell populations. A
481 bp fragment, spanning the NlaIII polymorphic site, was
amplified by PCR from MSCs genomic DNA. After gel
purification on a 1.5% agarose gel the fragment was incubated
at 37uC for 3 hrs in the appropriate digestion buffer with or
without 10,000 U of NlaIII. Fragment size analysis was performed
on a 2% agarose gel, first lane of each gel shows Lambda DNA/
BstE II Digest marker, fragment size is indicated. C) DNA
sequence analysis of the same PCR products. Double G/A pick
shows heterozygosity.
Found at: doi:10.1371/journal.pone.0007904.s003 (1.20 MB TIF)
Table S1 List of primers used.
Found at: doi:10.1371/journal.pone.0007904.s004 (0.03 MB
DOC)
Table S2 List of probesets differentially expressed in human
MSCs expressing SYT-SSX1 or an empty vector, 12 days after the
infection and puromycin selection. A) Lists of the probesets that
are differentially expressed with an FDR of 1% and a mean fold
change .2. The four human MSCs batches were analyzed
together with rank products (MSCs rankproduct). B) Lists of the
probesets that are differentially expressed with a fold-change
greater than 2 in each individual batch of human MSCs (MSCs
b1–b4).
Found at: doi:10.1371/journal.pone.0007904.s005 (0.49 MB
XLS)
Table S3 List of Gene Ontology (GO) terms over-represented in
the single-batch lists (MSCs batch 1-batch 4) and the lists derived
from the rank-product analysis (MSCs rankproduct).
Found at: doi:10.1371/journal.pone.0007904.s006 (1.74 MB
TXT)
Table S4 Overlap of the lists of differentially expressed genes in
the single-batch lists (MSCs b1–b4) and the lists derived from the
rank-product analysis (MSCs rankproduct) with the databases of
imprinted genes (Geneimprint and Otago).
Found at: doi:10.1371/journal.pone.0007904.s007 (0.07 MB
XLS)
Table S5 Overlap of the lists of differentially expressed genes in
the single-batch lists (MSCs b1–b4) and the lists derived from the
rank-product analysis (MSCs rankproduct) with the genes whose
TSS lies within a CpG island.
Found at: doi:10.1371/journal.pone.0007904.s008 (0.76 MB
XLS)
Table S6 Overlap of the lists of differentially expressed genes in
the single-batch lists (MSCs b1–b4) and the lists derived from the
rank-product analysis (MSCs rankproduct) with the databases of
chromatin-related genes (ChromoDB)
Found at: doi:10.1371/journal.pone.0007904.s009 (0.05 MB
XLS)
Table S7 Overlap of the lists of differentially expressed genes in
the single-batch (MSCs b1–b4) and in the lists derived from the
rank-product analysis (MSCs rankproduct) with the lists of various
recently published stemness markers.
Found at: doi:10.1371/journal.pone.0007904.s010 (0.77 MB
XLS)
Table S8 Overlap of the lists of differentially expressed genes in
the single-batch lists (MSCs b1–b4) and the lists derived from the
rank-product analysis (MSCs rankproduct) with the sarcoma
signatures identified in Francis et al, 2007, BMC Genomics 8: 73.
Found at: doi:10.1371/journal.pone.0007904.s011 (0.88 MB
XLS)
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